Regular price
$259.99 USD
Sale price
$259.99 USD
Regular price
Sold out
Unit price

Shipped from Canada.


What is this medication?

Mesalamine (Delayed/Extended Release Multimatrix Tablet), Mezavant/Lialda
5-Aminosalicylic Acid Derivative

Officially indicated to treat ulcerative colitis (moderate).

Brand Name US: Lialda
Canadian Equivalent:

How does this medication work? 

Mesalamine is a 5-aminosalicylic acid derivative that is a combined delayed and extended release form of Mesalamine and has been found to exhibit anti-inflammatory properties.  The exact mechanism of action is unknown; but it is thought to modulate local inflammatory mediators such as leukotrienes and tumor necrosis factor.  

How should I take this medication? 

Ulcerative Colitis (Treatment, Maintenance, Remission)
Oral: Take 2400mg to 4800mg once daily for 6 to 8 weeks.

How to Take:  The tablets should be swallowed whole and not crushed or chewed and taken with a meal for 6 to 8 weeks.

What should I watch for while using this medication? 

Use with caution in patients with pericarditis and myocarditis 

Discontinue use in patients who experience hypersensitivity reactions which may include hepatitis, myocarditis, pericarditis, nephritis, hematologic abnormalities and/or pneumonitis.

May cause photosensitivity, renal and hepatic impairment

What if I miss a dose?

If you miss a dose of medication, try to take it as soon as possible. However, if it is almost time for your next dose, take only that scheduled dose. Do not take double or extra doses.

How should I store this medication?

Keep out of the reach of children at all times. Store at room temperature, 59 to 86° F (15 to 30° C). Protect from light. Keep the container tightly closed. Properly dispose of any unused medication after the expiration date.

What are the possible side effects of using this medication?

The extent of side effects attributed to mesalamine are dependent on the dosage form, dose, and patient type:


Central Nervous System: Headache (3% to 14%)

Gastrointestinal: Eructation (≤26%), abdominal pain (oral: 2% to 21%, children & adolescents: 10%; rectal: 5%), constipation (≤11%)

Respiratory: Nasopharyngitis (children and adolescents: 15%; adults: 1% to 4%)